AstraZeneca announced the US Food and Drug Administration (FDA) approved once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes.
Management said the new medicine is indicated as an adjunct to diet and exercise to improve blood sugar level control in adults with type-2 diabetes with inadequate control with dapagliflozin (10mg) or who are already treated with dapagliflozin and saxagliptin.
AstraZeneca Head of Cardiovascular and Metabolic Diseases, Global Medicines Development Elisabeth Bjork said: “Type-2 diabetes is a complex disease that is at epidemic proportions, affecting more than 29 million people in the US alone.
“The approval of Qtern is good news for patients who may benefit from improved glycaemic control by adding a DPP-4 inhibitor to a SGLT-2 inhibitor in a convenient once-daily tablet.”
The company reported that SGLT-2 inhibitors help patients achieve improved glycaemic control by reducing reabsorption of glucose from the blood and enabling its removal via the urine.
SGLT-2 inhibitors, including Farxiga (dapagliflozin), demonstrated reductions in HbA1c and have also been shown to reduce weight and blood pressure.
DPP-4 inhibitors reduced blood glucose as measured by HbA1c.
At 10:40am: (LON:AZN) AstraZeneca PLC share price was +66p at 4674.5p
Story provided by StockMarketWire.com